Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:CRSP's Cash-to-Debt is ranked higher than
65% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:CRSP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CRSP' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.07  Med: No Debt Max: No Debt
Current: No Debt
4.07
No Debt
Equity-to-Asset 0.75
NAS:CRSP's Equity-to-Asset is ranked higher than
59% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NAS:CRSP: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CRSP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.22  Med: 0.66 Max: 0.78
Current: 0.75
-0.22
0.78
Interest Coverage No Debt
NAS:CRSP's Interest Coverage is ranked higher than
57% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CRSP: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:CRSP' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 11.73
Beneish M-Score: -1.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -233.82
NAS:CRSP's Operating Margin % is ranked lower than
58% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NAS:CRSP: -233.82 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CRSP' s Operating Margin % Range Over the Past 10 Years
Min: -10416.6  Med: -1319.33 Max: -157.69
Current: -233.82
-10416.6
-157.69
Net Margin % -245.56
NAS:CRSP's Net Margin % is ranked lower than
59% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NAS:CRSP: -245.56 )
Ranked among companies with meaningful Net Margin % only.
NAS:CRSP' s Net Margin % Range Over the Past 10 Years
Min: -10325.1  Med: -448.82 Max: -166.74
Current: -245.56
-10325.1
-166.74
ROE % -40.73
NAS:CRSP's ROE % is ranked higher than
51% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:CRSP: -40.73 )
Ranked among companies with meaningful ROE % only.
NAS:CRSP' s ROE % Range Over the Past 10 Years
Min: -40.73  Med: -27.63 Max: -22.75
Current: -40.73
-40.73
-22.75
ROA % -28.76
NAS:CRSP's ROA % is ranked higher than
55% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:CRSP: -28.76 )
Ranked among companies with meaningful ROA % only.
NAS:CRSP' s ROA % Range Over the Past 10 Years
Min: -410.22  Med: -26.94 Max: -9.19
Current: -28.76
-410.22
-9.19
ROC (Joel Greenblatt) % -458.56
NAS:CRSP's ROC (Joel Greenblatt) % is ranked higher than
52% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:CRSP: -458.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CRSP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3872.44  Med: -334.01 Max: -131.23
Current: -458.56
-3872.44
-131.23
3-Year EBITDA Growth Rate -89.60
NAS:CRSP's 3-Year EBITDA Growth Rate is ranked lower than
94% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:CRSP: -89.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CRSP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -89.6  Med: -89.6 Max: -89.6
Current: -89.6
GuruFocus has detected 1 Warning Sign with CRISPR Therapeutics AG NAS:CRSP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CRSP's 30-Y Financials

Financials (Next Earnings Date: 2018-11-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

CRSP Guru Trades in Q3 2017

John Paulson Sold Out
» More
Q4 2017

CRSP Guru Trades in Q4 2017

Pioneer Investments 3,200 sh (New)
» More
Q1 2018

CRSP Guru Trades in Q1 2018

Paul Tudor Jones 8,608 sh (New)
Pioneer Investments 2,800 sh (-12.50%)
» More
Q2 2018

CRSP Guru Trades in Q2 2018

Jim Simons 171,100 sh (New)
Pioneer Investments 3,200 sh (+14.29%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CRSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

CRISPR Therapeutics AG does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:RARE, NAS:IMMU, XSWX:GALE, SZSE:002821, XBRU:ARGX, NYSE:EBS, NAS:ONCE, NAS:FOLD, NAS:ANAB, NAS:PBYI, NAS:ASND, NAS:HALO, TSE:4974, NAS:CBPO, NAS:GBT, SZSE:300009, SHSE:600161, NAS:ACAD, XSWX:IDIA, NAS:AKCA » details
Traded in other countries:1CG.Germany,
Headquarter Location:Switzerland
CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.

CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.

Top Ranked Articles about CRISPR Therapeutics AG

Treating Genetic Diseases in Utero Could Change the CRISPR Space CRISPR stocks have been plagued with clinical holds by the FDA. But what if the treatments these speculative companies are working on can be applied in utero? New research shows they can
Genetic disorders are quite a daunting disease group to treat, but there is one major overlooked advantage in developing treatments for this disease group over others. Genetic diseases can be screened for in utero. So what? Thanks to new research published in the journal Nature Medicine, we know that they can be treated in utero as well. Read more...
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes
CRISPR Therapeutics to Present at Upcoming Investor Conferences
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results
CRISPR Therapeutics to Participate in Three June Conferences

Ratios

vs
industry
vs
history
PB Ratio 6.60
CRSP's PB Ratio is ranked lower than
75% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CRSP: 6.60 )
Ranked among companies with meaningful PB Ratio only.
CRSP' s PB Ratio Range Over the Past 10 Years
Min: 2.56  Med: 4.34 Max: 12.1
Current: 6.6
2.56
12.1
PS Ratio 40.82
CRSP's PS Ratio is ranked lower than
75% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CRSP: 40.82 )
Ranked among companies with meaningful PS Ratio only.
CRSP' s PS Ratio Range Over the Past 10 Years
Min: 18.58  Med: 66.25 Max: 168.21
Current: 40.82
18.58
168.21
EV-to-EBIT -16.41
CRSP's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CRSP: -16.41 )
Ranked among companies with meaningful EV-to-EBIT only.
CRSP' s EV-to-EBIT Range Over the Past 10 Years
Min: -40  Med: -17.4 Max: -7.5
Current: -16.41
-40
-7.5
EV-to-EBITDA -17.06
CRSP's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CRSP: -17.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRSP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.2  Med: -18.2 Max: -8
Current: -17.06
-42.2
-8
EV-to-Revenue 38.73
CRSP's EV-to-Revenue is ranked lower than
72% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CRSP: 38.73 )
Ranked among companies with meaningful EV-to-Revenue only.
CRSP' s EV-to-Revenue Range Over the Past 10 Years
Min: 12.8  Med: 50.25 Max: 112.3
Current: 38.73
12.8
112.3
Current Ratio 17.89
CRSP's Current Ratio is ranked higher than
89% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CRSP: 17.89 )
Ranked among companies with meaningful Current Ratio only.
CRSP' s Current Ratio Range Over the Past 10 Years
Min: 0.45  Med: 17.12 Max: 24.42
Current: 17.89
0.45
24.42
Quick Ratio 17.89
CRSP's Quick Ratio is ranked higher than
89% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CRSP: 17.89 )
Ranked among companies with meaningful Quick Ratio only.
CRSP' s Quick Ratio Range Over the Past 10 Years
Min: 0.45  Med: 17.12 Max: 24.42
Current: 17.89
0.45
24.42
Days Sales Outstanding 9.27
CRSP's Days Sales Outstanding is ranked higher than
90% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. CRSP: 9.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRSP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.27  Med: 223.14 Max: 500.95
Current: 9.27
9.27
500.95

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.50
CRSP's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CRSP: -11.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRSP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.5  Med: -11.5 Max: -11.5
Current: -11.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.56
CRSP's Price-to-Net-Cash is ranked lower than
60% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. CRSP: 7.56 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRSP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.89  Med: 4.77 Max: 11.94
Current: 7.56
3.89
11.94
Price-to-Net-Current-Asset-Value 7.22
CRSP's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. CRSP: 7.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRSP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.68  Med: 4.61 Max: 11.41
Current: 7.22
3.68
11.41
Price-to-Tangible-Book 6.61
CRSP's Price-to-Tangible-Book is ranked lower than
69% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. CRSP: 6.61 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRSP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.25  Med: 4.04 Max: 10.44
Current: 6.61
3.25
10.44
Price-to-Median-PS-Value 0.62
CRSP's Price-to-Median-PS-Value is ranked higher than
62% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CRSP: 0.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRSP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.95 Max: 2.28
Current: 0.62
0.35
2.28
Earnings Yield (Greenblatt) % -6.10
CRSP's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CRSP: -6.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRSP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.3  Med: -5.75 Max: -2.5
Current: -6.1
-13.3
-2.5

More Statistics

Revenue (TTM) (Mil) $37.16
EPS (TTM) $ -2.05
Volatility93.28%
52-Week Range $16.51 - 73.90
Shares Outstanding (Mil)47.33

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 23 91 109 179
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -2.58 -1.87 -3.04 -4.22
EPS without NRI ($) -2.58 -1.87 -3.04 -4.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}